2018: A continued year of growth

  • 6.6% revenue growth increase in actual terms to £68.3m (2017: £64.1m)
  • 3.5% revenue growth at constant currency to £66.4m (2017: £64.1m)
  • One point increase to 14% in market share in European business (2017: 13%)
  • 10% compound annual growth in net sales over 19 years since the company formed
  • 26% increase in operating profit (pre-R&D) to £9.3m (2017: £7.4m)
  • Cash at 30 June £15.5m (2017: £22.1m) prior to the July 2018 fundraising of £10.2m net of expenses

Related links

link-img
Annual Report 2018

Click here to read this years Annual Report.

Annual Report 2018
link-img
Investors

Allergy Therapeutics Investor Relations Centre.

Overview
link-img
Get in touch

Contact us.

Get in touch